A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2026

Primary Completion Date

July 14, 2028

Study Completion Date

July 14, 2028

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

JNJ-90301900

JNJ-90301900 will administered via intratumoral and/or intranodal injection.

DRUG

Cisplatin

Cisplatin will be administered intravenously.

RADIATION

Intensity Modulated Radiation Therapy (IMRT)

IMRT radiation therapy will be administered.

All Listed Sponsors

lead

Johnson & Johnson Enterprise Innovation Inc.

INDUSTRY